File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1586/erc.11.171
- Scopus: eid_2-s2.0-82755161193
- PMID: 22103878
- WOS: WOS:000216612500017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The proarrhythmic risk of cell therapy for cardiovascular diseases
Title | The proarrhythmic risk of cell therapy for cardiovascular diseases |
---|---|
Authors | |
Keywords | cardiac regeneration cardiovascular diseases proarrhythmia stem cell transplantation |
Issue Date | 2011 |
Publisher | Expert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=2 |
Citation | Expert Review Of Cardiovascular Therapy, 2011, v. 9 n. 12, p. 1593-1601 How to Cite? |
Abstract | Stem cell therapy is an emerging therapeutic approach for the treatment of cardiovascular diseases. Experimental studies have demonstrated that different types of stem cells, including bone marrow-derived cells, mesenchymal stem cells, skeletal myoblasts, and cardiac progenitor cells and embryonic stem cells, can improve cardiac function after myocardial injuries. Nevertheless, the potential proarrhythmic risk after stem cell transplantation remains a major concern. Several mechanisms, including the immaturity of electrical phenotypes of the transplanted cardiomyocytes, poor cell-cell coupling and cardiac nerve sprouting, may contribute to arrhythmogenic risk after stem cell transplantation. This review summarizes the potential theoretical arrhythmogenic mechanisms associated with different types of stem cells for the treatment of cardiovascular diseases. Nevertheless, current experimental and clinical data on the proarrhythmic risk for different types of stem cell transplantation are limited, and await further experimental and clinical investigation. © 2011 Expert Reviews Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/163428 |
ISSN | 2023 Impact Factor: 1.8 2023 SCImago Journal Rankings: 0.635 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, Y | en_US |
dc.contributor.author | Tse, HF | en_US |
dc.date.accessioned | 2012-09-05T05:31:15Z | - |
dc.date.available | 2012-09-05T05:31:15Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | Expert Review Of Cardiovascular Therapy, 2011, v. 9 n. 12, p. 1593-1601 | en_US |
dc.identifier.issn | 1477-9072 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163428 | - |
dc.description.abstract | Stem cell therapy is an emerging therapeutic approach for the treatment of cardiovascular diseases. Experimental studies have demonstrated that different types of stem cells, including bone marrow-derived cells, mesenchymal stem cells, skeletal myoblasts, and cardiac progenitor cells and embryonic stem cells, can improve cardiac function after myocardial injuries. Nevertheless, the potential proarrhythmic risk after stem cell transplantation remains a major concern. Several mechanisms, including the immaturity of electrical phenotypes of the transplanted cardiomyocytes, poor cell-cell coupling and cardiac nerve sprouting, may contribute to arrhythmogenic risk after stem cell transplantation. This review summarizes the potential theoretical arrhythmogenic mechanisms associated with different types of stem cells for the treatment of cardiovascular diseases. Nevertheless, current experimental and clinical data on the proarrhythmic risk for different types of stem cell transplantation are limited, and await further experimental and clinical investigation. © 2011 Expert Reviews Ltd. | en_US |
dc.language | eng | en_US |
dc.publisher | Expert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=2 | en_US |
dc.relation.ispartof | Expert Review of Cardiovascular Therapy | en_US |
dc.subject | cardiac regeneration | - |
dc.subject | cardiovascular diseases | - |
dc.subject | proarrhythmia | - |
dc.subject | stem cell | - |
dc.subject | transplantation | - |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Adult Stem Cells - Cytology - Transplantation | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Arrhythmias, Cardiac - Etiology | en_US |
dc.subject.mesh | Cardiovascular Diseases - Physiopathology - Therapy | en_US |
dc.subject.mesh | Cell Differentiation | en_US |
dc.subject.mesh | Heart Failure - Etiology - Prevention & Control - Therapy | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Myocytes, Cardiac - Cytology - Transplantation | en_US |
dc.subject.mesh | Stem Cell Transplantation - Adverse Effects | en_US |
dc.subject.mesh | Transplantation, Autologous | en_US |
dc.title | The proarrhythmic risk of cell therapy for cardiovascular diseases | en_US |
dc.type | Article | en_US |
dc.identifier.email | Tse, HF:hftse@hkucc.hku.hk | en_US |
dc.identifier.authority | Tse, HF=rp00428 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1586/erc.11.171 | en_US |
dc.identifier.pmid | 22103878 | - |
dc.identifier.scopus | eid_2-s2.0-82755161193 | en_US |
dc.identifier.hkuros | 225174 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-82755161193&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 9 | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.spage | 1593 | en_US |
dc.identifier.epage | 1601 | en_US |
dc.identifier.isi | WOS:000216612500017 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Liu, Y=36071722500 | en_US |
dc.identifier.scopusauthorid | Tse, HF=7006070805 | en_US |
dc.identifier.issnl | 1477-9072 | - |